Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer
Last updated: 24 Dec 2024
10.21608/jvmr.2024.336602.1109
B-cell lymphoma 2 protein (Bcl-2), Chalcone, non-small cell lung cancer (NSCLC), Multi-drug resistance (MDR)
Omar
Elrehany
Mahmoud
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
o_elrehany@yahoo.com
Minia
Al-Shaimaa
Ahmed
Faissal
Department of Pharmacology, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
shaimaa.faissal@minia.edu.eg
Minia
Maiiada
Nazmy
Hassan
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
maiiada_nazmy@mu.edu.eg
Minya
31
2
51824
2024-12-01
2024-11-16
2024-12-01
52
55
2357-0512
2357-0520
https://jvmr.journals.ekb.eg/article_393191.html
https://jvmr.journals.ekb.eg/service?article_code=393191
5
Review article
894
Journal
Journal of Veterinary Medical Research
https://jvmr.journals.ekb.eg/
Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer
Details
Type
Article
Created At
24 Dec 2024